CA2883751C - Methods of treating alzheimer's disease and pharmaceutical compositions thereof - Google Patents

Methods of treating alzheimer's disease and pharmaceutical compositions thereof Download PDF

Info

Publication number: CA2883751C
Authority: CA; Canada
Prior art keywords: pharmaceutically acceptable; tetrafluoropropoxy; indol; fluoro; ethyl
Prior art date: 2012-09-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CA2883751A

Other languages

English (en)

French (fr)

Other versions

CA2883751A1 (en

Inventor

Ellen Schmidt

Johan AREBERG

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

H Lundbeck AS

Original Assignee

H Lundbeck AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-09

Filing date

2013-09-06

Publication date

2020-11-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49118521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2883751(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-09-06 Application filed by H Lundbeck AS filed Critical H Lundbeck AS

2014-03-13 Publication of CA2883751A1 publication Critical patent/CA2883751A1/en

2020-11-24 Application granted granted Critical

2020-11-24 Publication of CA2883751C publication Critical patent/CA2883751C/en

Status Active legal-status Critical Current

2033-09-06 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA2883751A 2012-09-09 2013-09-06 Methods of treating alzheimer's disease and pharmaceutical compositions thereof Active CA2883751C (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201261698664P	2012-09-09	2012-09-09
US61/698,664		2012-09-09
US201361782084P	2013-03-14	2013-03-14
US61/782,084		2013-03-14
PCT/EP2013/068516 WO2014037532A1 (en)	2012-09-09	2013-09-06	Methods of treating alzheimer's disease and pharmaceutical compositions thereof

Publications (2)

Publication Number	Publication Date
CA2883751A1 CA2883751A1 (en)	2014-03-13
CA2883751C true CA2883751C (en)	2020-11-24

Family

ID=49118521

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2883751A Active CA2883751C (en)	2012-09-09	2013-09-06	Methods of treating alzheimer's disease and pharmaceutical compositions thereof

Country Status (33)

Country	Link
US (4)	US9375418B2 (2)
EP (1)	EP2892563B1 (2)
JP (2)	JP6693744B2 (2)
KR (2)	KR102342127B1 (2)
CN (1)	CN104619344A (2)
AP (1)	AP2015008306A0 (2)
AU (1)	AU2013311573B2 (2)
BR (1)	BR112015005117B1 (2)
CA (1)	CA2883751C (2)
CL (1)	CL2015000578A1 (2)
CY (1)	CY1121062T1 (2)
DK (1)	DK2892563T3 (2)
EA (1)	EA030448B1 (2)
ES (1)	ES2703630T3 (2)
GE (1)	GEP201706776B (2)
HR (1)	HRP20182069T1 (2)
IL (1)	IL237369B (2)
JO (1)	JO3459B1 (2)
LT (1)	LT2892563T (2)
MX (1)	MX368305B (2)
MY (1)	MY182539A (2)
NI (1)	NI201500031A (2)
NZ (1)	NZ630589A (2)
PL (1)	PL2892563T3 (2)
PT (1)	PT2892563T (2)
RS (1)	RS58104B1 (2)
RU (1)	RU2675786C2 (2)
SG (1)	SG11201501774QA (2)
SI (1)	SI2892563T1 (2)
SM (1)	SMT201800678T1 (2)
TN (1)	TN2015000076A1 (2)
TW (1)	TWI632909B (2)
WO (1)	WO2014037532A1 (2)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE602004000260T2 (de)	2003-07-22	2006-08-24	Arena Pharmaceuticals, Inc., San Diego	Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
EP2508177A1 (en)	2007-12-12	2012-10-10	Glaxo Group Limited	Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en)	2008-04-02	2011-01-27	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en)	2008-10-28	2015-09-08	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
JO3459B1 (ar)	2012-09-09	2020-07-05	H Lundbeck As	تركيبات صيدلانية لعلاج مرض الزهايمر
US9604982B2 (en)	2013-03-14	2017-03-28	Janssen Pharmaceutica Nv	P2X7 modulators
TWI644671B (zh)	2013-03-14	2018-12-21	比利時商健生藥品公司	Ｐ２ｘ７調節劑
US9040534B2 (en)	2013-03-14	2015-05-26	Janssen Pharmaceutica Nv	[1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JO3509B1 (ar)	2013-03-14	2020-07-05	Janssen Pharmaceutica Nv	معدلات p2x7
ES2845473T3 (es)	2013-03-14	2021-07-26	Boehringer Ingelheim Int	(Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C
JO3639B1 (ar)	2014-07-04	2020-08-27	H Lundbeck As	صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
EP3511331A1 (en)	2014-09-12	2019-07-17	Boehringer Ingelheim International GmbH	Spirocyclic inhibitors of cathepsin c
WO2016039977A1 (en)	2014-09-12	2016-03-17	Janssen Pharmaceutica Nv	P2x7 modulators
AU2015315693B2 (en)	2014-09-12	2020-01-16	Janssen Pharmaceutica Nv	P2X7 modulating n-acyl-triazolopyrazines
CN105175307A (zh) *	2014-11-18	2015-12-23	苏州晶云药物科技有限公司	Lu AE58054的盐酸盐晶型A及其制备方法和用途
JP2018515607A (ja) *	2015-05-07	2018-06-14	アクソファントサイエンシーズゲーエムベーハーＡｘｏｖａｎｔＳｃｉｅｎｃｅｓＧｍｂｈ	神経変性疾患を処置する組成物および方法
US10022355B2 (en)	2015-06-12	2018-07-17	Axovant Sciences Gmbh	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112018000728A2 (pt)	2015-07-15	2018-09-04	Axovant Sciences Gmbh	resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
US10383849B2 (en) *	2016-04-26	2019-08-20	H. Lundbeck A/S	Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in Parkinson's disease patients
US10864191B2 (en)	2016-05-11	2020-12-15	H. Lundbeck A/S	5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
EA036347B1 (ru)	2016-05-18	2020-10-29	Сувен Лайф Сайенсиз Лимитед	Комбинация чистых антагонистов 5-ht6 рецепторов с ингибиторами ацетилхолинэстеразы
CN106309436A (zh) *	2016-07-25	2017-01-11	宁波大学	可用作乙酰胆碱酯酶抑制剂的色胺衍生物及其用途
CN107118146B (zh) *	2017-04-13	2019-09-03	宁波大学	一种6-溴色胺衍生物及其制备方法和用途
BR112019001145A2 (pt) *	2017-05-24	2019-04-30	H. Lundbeck A/S	combinação de um antagonista do receptor 5-ht6 e de um inibidor de acetilcolinesterase para uso no tratamento da doença de alzheimer em uma subpopulação de pacientes portadores de alelos de apoe4
MY205440A (en)	2018-09-28	2024-10-21	Janssen Pharmaceutica Nv	Monoacylglycerol lipase modulators
KR20210069079A (ko)	2018-09-28	2021-06-10	얀센 파마슈티카 엔.브이.	모노아실글리세롤 리파아제 조절제
JP7697934B2 (ja)	2019-09-30	2025-06-24	ヤンセンファーマシューティカエヌ．ベー．	放射線標識されたｍｇｌｐｅｔリガンド
NL2024431B1 (en)	2019-12-11	2021-09-07	Sulfateq Bv	Compounds for treatment of alzheimer’s disease
BR112022019077A2 (pt)	2020-03-26	2022-12-27	Janssen Pharmaceutica Nv	Moduladores da monoacilglicerol lipase
EP3960174B1 (en)	2020-08-28	2024-10-30	Westfälische Wilhelms-Universität Münster	Parasympathetic active phenyl-glycosid-substituted hydroxy-methyl-piperidine and -pyrrolidine alkaloids for medicinal use
WO2025198622A1 (en) *	2024-03-22	2025-09-25	Queen Aaric	Magnesium and lidocaine composition

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3597149A (en)	1969-04-29	1971-08-03	Showa Denko Kk	Inhibition of gas-fume fading of dyed cellulose acetate material
FR2181559A1 (en)	1972-04-28	1973-12-07	Aec Chimie Organique Bio	N-Phenylalkyl-N-3-indolylalkyl-alkylamines - with sedative, neuroleptic, analgesic, hypotensive, antiserotonin, adrenolytic activity
JPS5764632A (en)	1980-10-09	1982-04-19	Mitsui Toatsu Chem Inc	Novel 2-arylethyl ether derivative and thioether derivative, their production and insecticide and acaricide
DE3632329A1 (de)	1986-09-24	1988-03-31	Bayer Ag	Substituierte phenylsulfonamide
US5202336A (en)	1986-09-24	1993-04-13	Bayer Aktiengesellschaft	Antiflammatory quinolin methoxy phenylsulphonamides
SE9103745D0 (sv)	1991-12-18	1991-12-18	Wikstroem Haakan	Aryl-triflates and related compounds
DE69411143T2 (de)	1993-09-01	1998-10-22	Allelix Biopharma	Tryptamin analoge mit 5-ht1d selektivität
US5504101A (en)	1994-05-06	1996-04-02	Allelix Biopharmaceuticals, Inc.	5-HT-1D receptor ligands
AU752008B2 (en)	1997-09-29	2002-09-05	Aventis Pharmaceuticals Inc.	Aminoalkylphenol derivatives and related compounds
GB9820113D0 (en)	1998-09-15	1998-11-11	Merck Sharp & Dohme	Therapeutic agents
CA2353962C (en)	1998-12-11	2009-09-29	Virginia Commonwealth University	Selective 5-ht6 receptor ligands
CZ20012502A3 (cs)	1999-01-13	2002-03-13	Millennium Pharmaceuticals, Inc.	Funkcionalizované heterocykly jako modulátory chemokinových receptorů
US6750348B1 (en)	1999-03-24	2004-06-15	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds
DK1859798T3 (en)	2001-03-29	2016-03-21	Lilly Co Eli	N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
RU2252936C2 (ru)	2002-12-05	2005-05-27	Институт физиологически активных веществ РАН	S-замещенные n-1-[(гетеро)арил]алкил-n`-[(гетеро)арил]алкилизотиомочевины, способ их получения, фармацевтическая композиция, способ изучения глутаматэргической системы, способы лечения (варианты)
PE20071143A1 (es) *	2006-01-13	2008-01-20	Wyeth Corp	Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
JP2009541423A (ja)	2006-06-23	2009-11-26	ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ	コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ
AR061637A1 (es)	2006-06-26	2008-09-10	Epix Delaware Inc	Composiciones y metodos de tratamiento de trastornos del snc
US20120184532A1 (en) *	2009-07-23	2012-07-19	Shire Llc	Galantamine amino acid and peptide prodrugs and uses thereof
TW201139370A (en)	2009-12-23	2011-11-16	Lundbeck & Co As H	Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar)	2012-09-09	2020-07-05	H Lundbeck As	تركيبات صيدلانية لعلاج مرض الزهايمر

2013
- 2013-08-21 JO JOP/2013/0248A patent/JO3459B1/ar active
- 2013-09-06 MX MX2015002879A patent/MX368305B/es active IP Right Grant
- 2013-09-06 CN CN201380046768.6A patent/CN104619344A/zh active Pending
- 2013-09-06 SI SI201331303T patent/SI2892563T1/sl unknown
- 2013-09-06 KR KR1020207034028A patent/KR102342127B1/ko active Active
- 2013-09-06 JP JP2015530420A patent/JP6693744B2/ja active Active
- 2013-09-06 EP EP13759195.4A patent/EP2892563B1/en active Active
- 2013-09-06 MY MYPI2015000575A patent/MY182539A/en unknown
- 2013-09-06 PL PL13759195T patent/PL2892563T3/pl unknown
- 2013-09-06 DK DK13759195.4T patent/DK2892563T3/en active
- 2013-09-06 GE GEAP201313752A patent/GEP201706776B/en unknown
- 2013-09-06 SM SM20180678T patent/SMT201800678T1/it unknown
- 2013-09-06 TW TW102132182A patent/TWI632909B/zh active
- 2013-09-06 RU RU2015107877A patent/RU2675786C2/ru active
- 2013-09-06 CA CA2883751A patent/CA2883751C/en active Active
- 2013-09-06 NZ NZ630589A patent/NZ630589A/en unknown
- 2013-09-06 BR BR112015005117-0A patent/BR112015005117B1/pt active IP Right Grant
- 2013-09-06 HR HRP20182069TT patent/HRP20182069T1/hr unknown
- 2013-09-06 KR KR1020157007345A patent/KR20150065680A/ko not_active Ceased
- 2013-09-06 PT PT13759195T patent/PT2892563T/pt unknown
- 2013-09-06 ES ES13759195T patent/ES2703630T3/es active Active
- 2013-09-06 SG SG11201501774QA patent/SG11201501774QA/en unknown
- 2013-09-06 WO PCT/EP2013/068516 patent/WO2014037532A1/en not_active Ceased
- 2013-09-06 AP AP2015008306A patent/AP2015008306A0/xx unknown
- 2013-09-06 AU AU2013311573A patent/AU2013311573B2/en active Active
- 2013-09-06 EA EA201590353A patent/EA030448B1/ru not_active IP Right Cessation
- 2013-09-06 LT LTEP13759195.4T patent/LT2892563T/lt unknown
- 2013-09-06 RS RS20181571A patent/RS58104B1/sr unknown
- 2013-09-09 US US14/021,033 patent/US9375418B2/en active Active
2015
- 2015-02-23 IL IL237369A patent/IL237369B/en active IP Right Grant
- 2015-03-02 TN TNP2015000076A patent/TN2015000076A1/fr unknown
- 2015-03-06 NI NI201500031A patent/NI201500031A/es unknown
- 2015-03-06 CL CL2015000578A patent/CL2015000578A1/es unknown
2016
- 2016-03-30 US US15/084,712 patent/US9687473B2/en active Active
- 2016-06-28 US US15/194,947 patent/US9789085B2/en active Active
2017
- 2017-09-06 US US15/696,880 patent/US10660878B2/en active Active
2018
- 2018-12-06 JP JP2018228631A patent/JP2019059760A/ja active Pending
- 2018-12-21 CY CY181101390T patent/CY1121062T1/el unknown

Also Published As

Publication number	Publication date
BR112015005117A2 (pt)	2017-07-04
IL237369B (en)	2018-11-29
SG11201501774QA (en)	2015-05-28
MX2015002879A (es)	2015-07-06
CA2883751A1 (en)	2014-03-13
US20160256437A1 (en)	2016-09-08
AU2013311573B2 (en)	2017-10-12
BR112015005117B1 (pt)	2022-06-21
WO2014037532A1 (en)	2014-03-13
AU2013311573A1 (en)	2015-03-12
RU2675786C2 (ru)	2018-12-25
TW201414474A (zh)	2014-04-16
US10660878B2 (en)	2020-05-26
CY1121062T1 (el)	2019-12-11
TN2015000076A1 (en)	2016-06-29
KR20150065680A (ko)	2015-06-15
US20180071254A1 (en)	2018-03-15
DK2892563T3 (en)	2019-01-21
RS58104B1 (sr)	2019-02-28
SI2892563T1 (sl)	2019-02-28
NI201500031A (es)	2016-02-15
JP2019059760A (ja)	2019-04-18
US9687473B2 (en)	2017-06-27
JP6693744B2 (ja)	2020-05-13
AU2013311573A8 (en)	2015-03-19
HK1212217A1 (en)	2016-06-10
AP2015008306A0 (en)	2015-03-31
LT2892563T (lt)	2019-01-10
EP2892563B1 (en)	2018-11-14
MY182539A (en)	2021-01-25
CL2015000578A1 (es)	2015-05-15
US20160354343A1 (en)	2016-12-08
KR102342127B1 (ko)	2021-12-21
NZ630589A (en)	2015-12-24
KR20200137028A (ko)	2020-12-08
US9375418B2 (en)	2016-06-28
IL237369A0 (en)	2015-04-30
EA201590353A1 (ru)	2016-03-31
EA030448B1 (ru)	2018-08-31
US9789085B2 (en)	2017-10-17
RU2015107877A (ru)	2016-10-27
MX368305B (es)	2019-09-27
JO3459B1 (ar)	2020-07-05
GEP201706776B (en)	2017-11-27
HRP20182069T1 (hr)	2019-02-08
CN104619344A (zh)	2015-05-13
PL2892563T3 (pl)	2019-04-30
PT2892563T (pt)	2019-01-10
SMT201800678T1 (it)	2019-02-28
TWI632909B (zh)	2018-08-21
EP2892563A1 (en)	2015-07-15
US20140073681A1 (en)	2014-03-13
JP2015528471A (ja)	2015-09-28
ES2703630T3 (es)	2019-03-11

Legal Events

Date	Code	Title	Description
2018-05-23	EEER	Examination request	Effective date: 20180516
2024-07-26	MPN	Maintenance fee for patent paid	Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11
2024-07-26	U00	Fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240726
2024-07-26	U11	Full renewal or maintenance fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240726
2025-07-02	MPN	Maintenance fee for patent paid	Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12
2025-07-02	U00	Fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250702
2025-07-02	U11	Full renewal or maintenance fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250702

Publication	Publication Date	Title
CA2883751C (en)	2020-11-24	Methods of treating alzheimer's disease and pharmaceutical compositions thereof
JP2019059760A5 (2)	2019-06-27
JP2015528471A5 (2)	2016-10-20
FI3157527T3 (fi)	2023-07-25	Ezh2-inhibiittoreita lymfoman hoitoon
MX393855B (es)	2025-03-21	Terapia de combinación que comprende un inhibidor de raf y trametinib
EP4643882A3 (en)	2026-01-14	Capsid inhibitors for the prevention of hiv
MX2012007052A (es)	2012-07-30	Metodo para tratar fibrilacion atrial.
PH12020500543A1 (en)	2021-01-25	Nonracemic mixtures and uses thereof
PE20150161A1 (es)	2015-02-22	Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
MX2015001917A (es)	2015-10-29	Composiciones farmaceuticas de memantina.
PL1933833T3 (pl)	2011-09-30	Terapia do leczenia pęcherza nadreaktywnego
RU2013153140A (ru)	2015-06-10	Новая ассоциация между 4-{3-[цис-гексагидроциклопента[c] пиррол-2 (1н )- ил] пропокси} бензамидом и ингибитором ацетилхолинэстеразы и фармацевтические композиции, которые ее содержат
AU2020278236A8 (en)	2022-04-28	Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
MX362830B (es)	2019-02-14	Agente terapeutico o profilactico para enfermedades del tracto biliar.
ZA202000028B (en)	2025-09-25	Use of vibegron to treat overactive bladder
RU2009131745A (ru)	2011-02-27	Лекарственное средство для профилактического и/или терапевтического лечения деменции по типу альцгеймера
EP4442315A3 (en)	2024-11-20	Lta4h inhibitor for the treatment or prevention of hidradenitis suppurativa
FI3448430T3 (fi)	2023-06-20	Asetyylikoleeniesteraasi-inhibiittorin ja idalopirdiinin käyttö Parkinsonin taudin potilaiden kaatumisten vähentämiseksi
MX2018013477A (es)	2019-02-28	Acidos carboxilicos para tratar/prevenir una enfermedad de la piel.
MX2012003027A (es)	2012-04-19	Uso de derivados del indol como activadores de nurr-1, para su aplicacion como medicamento en el tratamiento de la enfermedad de parkinson.
RU2012114097A (ru)	2013-10-20	Терапевтический агент против хронической боли
WO2019035646A8 (ko)	2020-03-05	세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물
NZ727251A (en)	2023-06-30	Novel polymorphic form of n-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer’s
MA37957A1 (fr)	2017-01-31	Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées
TN2013000336A1 (en)	2015-01-20	5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy.